BLUE Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

SPRZEDAż 117869 min ago

@ $1.019

Wydano: 14 vas. 2024 @ 16:30

Zwrot: -11.67%

Poprzedni sygnał: vas. 12 - 19:12

Poprzedni sygnał: Kupno

Zwrot: -3.90 %

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	7.10M
Średni wolumen	8.20M
Kapitalizacja rynkowa	173.43M
EPS	$0 ( 2024-04-03 )
Następna data zysków	( $-0.470 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.430
ATR14	$0.00200 (0.22%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Colvin Richard A	Buy	199 000	Stock Option (right to buy)
2024-03-01	Colvin Richard A	Sell	6 770	Common Stock
2024-03-01	Vittiglio Joseph	Buy	199 000	Stock Option (right to buy)
2024-03-01	Obenshain Andrew	Buy	650 000	Stock Option (right to buy)
2024-03-04	Obenshain Andrew	Sell	6 095	Common Stock

INSIDER POWER
92.32
Last 95 transactions
Buy: 3 237 593 \| Sell: 214 711

Wolumen Korelacja

Długi: -0.25 (neutral)

Krótki: -0.79 (moderate negative)

Signal:(41.481) Neutral

bluebird bio Inc Korelacja

10 Najbardziej pozytywne korelacje
ALXO	0.973
YJ	0.949
ORPH	0.947
PMVP	0.946
CSSEP	0.946
KNSA	0.945
NAKD	0.944
GOOD	0.944
IPA	0.943
GSMG	0.942

10 Najbardziej negatywne korelacje
CPAQ	-0.961
MCAA	-0.958
SCOB	-0.957
LGACU	-0.957
ABGI	-0.957
FICV	-0.957
AGGR	-0.957
LGAC	-0.957
LVRA	-0.955
KAII	-0.955

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

bluebird bio Inc Korelacja - Waluta/Towar

-0.60
( weak negative )

-0.73
( moderate negative )

0.00
( neutral )

-0.29
( neutral )

bluebird bio Inc Finanse

Annual	2022
Przychody:	$3.60M
Zysk brutto:	$-6.48M (-180.15 %)
EPS:	$-3.39

FY	2022
Przychody:	$3.60M
Zysk brutto:	$-6.48M (-180.15 %)
EPS:	$-3.39

FY	2021
Przychody:	$3.66M
Zysk brutto:	$-35.20M (-961.09 %)
EPS:	$-11.89

FY	2020
Przychody:	$250.73M
Zysk brutto:	$245.34M (97.85 %)
EPS:	$-9.95

Financial Reports:

No articles found.

bluebird bio Inc

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.